Table 3.
Rates of primary composite CV outcome and recurrent stroke by OSA clinical phenotype and CPAP treatment.
| Primary outcomea % (95%CI) | Stroke event % (95%CI) | |||||
|---|---|---|---|---|---|---|
| Phenotype | No or < 4 h CPAP | ≥ 4 h CPAP | P valueb | No or < 4 h CPAP | ≥ 4 h CPAP | P valueb |
| CeVD + DM | 21.11 (15.65–27.44) | 4.88 (0.6–16.53) | 0.015 | 12.06 (7.88–17.41) | 2.44 (0.06–12.86) | 0.066 |
| CAD + DM | 19.59 (15.23–24.58) | 23.71 (15.66–33.42) | 0.384 | 4.73 (2.61–7.81) | 4.12 (1.13–10.22) | 0.804 |
| CeVD | 12.6 (10.34–15.15) | 13.47 (8.99–19.11) | 0.745 | 7.4 (5.65–9.48) | 6.22 (3.25–10.61) | 0.568 |
| CAD | 17.88 (15.28–20.71) | 15.35 (10.93–20.7) | 0.374 | 2.13 (1.24–3.38) | 0.88 (0.11–3.13) | 0.217 |
CAD denotes coronary artery disease, CI confidence interval, CPAP continuous positive airway pressure, CeVD, cerebrovascular disease, CV cardiovascular, DM diabetes mellitus, OSA obstructive sleep apnoea.
Missing 26 patients without information on adherence.
a
The primary composite endpoint included death from cardiovascular causes, myocardial infarction, stroke, or hospitalisation for heart failure, unstable angina, and transient ischaemic attack.
b
The P values are based on Chi-square test or Fisher's exact test as appropriate.